For research use only. Not for therapeutic Use.
Isobavachalcone（Cat No.:I002599）is a naturally occurring chalcone derived from Psoralea corylifolia, known for its diverse pharmacological properties, including anticancer, antimicrobial, and anti-inflammatory effects. It acts by inhibiting key cellular pathways such as NF-κB and STAT3, making it valuable in cancer research for studying tumor growth suppression and apoptosis induction. Additionally, Isobavachalcone exhibits antioxidant activity, contributing to its potential in treating inflammatory diseases. Its broad biological activities make it a significant compound for exploring new therapeutic strategies in oncology, infectious diseases, and chronic inflammation.
| Catalog Number | I002599 |
| CAS Number | 20784-50-3 |
| Synonyms | (E)-1-[2,4-dihydroxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one |
| Molecular Formula | C20H20O4 |
| Purity | ≥95% |
| Target | NF-κB |
| Solubility | DMSO: ≤ 11 mg/mL |
| Storage | Store at -20°C |
| IUPAC Name | (E)-1-[2,4-dihydroxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one |
| InChI | InChI=1S/C20H20O4/c1-13(2)3-9-16-19(23)12-10-17(20(16)24)18(22)11-6-14-4-7-15(21)8-5-14/h3-8,10-12,21,23-24H,9H2,1-2H3/b11-6+ |
| InChIKey | DUWPGRAKHMEPCM-IZZDOVSWSA-N |
| SMILES | CC(=CCC1=C(C=CC(=C1O)C(=O)/C=C/C2=CC=C(C=C2)O)O)C |
| Reference | </br>1:Isobavachalcone Attenuates MPTP-Induced Parkinson/’s Disease in Mice by Inhibition of Microglial Activation through NF-κB Pathway. Jing H, Wang S, Wang M, Fu W, Zhang C, Xu D.PLoS One. 2017 Jan 6;12(1):e0169560. doi: 10.1371/journal.pone.0169560. eCollection 2017. PMID: 28060896 Free PMC Article</br>2:Isobavachalcone induces the apoptosis of gastric cancer cells via inhibition of the Akt and Erk pathways. Jin X, Shi YI.Exp Ther Med. 2016 Feb;11(2):403-408. Epub 2015 Dec 1. PMID: 26893622 Free PMC Article</br>3:Cytotoxicity of three naturally occurring flavonoid derived compounds (artocarpesin, cycloartocarpesin and isobavachalcone) towards multi-factorial drug-resistant cancer cells. Kuete V, Mbaveng AT, Zeino M, Fozing CD, Ngameni B, Kapche GD, Ngadjui BT, Efferth T.Phytomedicine. 2015 Nov 15;22(12):1096-102. doi: 10.1016/j.phymed.2015.07.006. Epub 2015 Aug 11. PMID: 26547532 </br>4:Enzymatic synthesis of novel isobavachalcone glucosides via a UDP-glycosyltransferase. Li HM, Lee JK, Nie LJ, Huo Q, Ma T, Sohng JK, Hong YS, Wu CZ.Arch Pharm Res. 2015 Dec;38(12):2208-15. doi: 10.1007/s12272-015-0658-8. Epub 2015 Sep 15. PMID: 26374247 </br>5:Isobavachalcone attenuates lipopolysaccharide-induced ICAM-1 expression in brain endothelial cells through blockade of toll-like receptor 4 signaling pathways. Lee KM, Kim JM, Baik EJ, Ryu JH, Lee SH.Eur J Pharmacol. 2015 May 5;754:11-8. doi: 10.1016/j.ejphar.2015.02.013. Epub 2015 Feb 19. PMID: 25704611 </br>6:Determination of isobavachalcone in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. Ma T, Nie LJ, Li HM, Huo Q, Zhang YX, Wu CZ.J Pharm Biomed Anal. 2015 Mar 25;107:50-5. doi: 10.1016/j.jpba.2014.12.023. Epub 2014 Dec 22. PMID: 25575171 </br>7:Structural elucidation of in vivo metabolites of isobavachalcone in rat by LC-ESI-MS(n) and LC-NMR. Su S, Wang Y, Bai L, Xia B, Li X, Tang Y, Xu P, Xue M.J Pharm Biomed Anal. 2015 Feb;104:38-46. doi: 10.1016/j.jpba.2014.11.010. Epub 2014 Nov 15. PMID: 25459757 </br>8:Study on structural and spectral properties of isobavachalcone and 4-hydroxyderricin by computational method. Rong Y, Wu J, Liu X, Zhao B, Wang Z.Spectrochim Acta A Mol Biomol Spectrosc. 2014 May 21;126:254-9. doi: 10.1016/j.saa.2014.02.013. Epub 2014 Feb 18. PMID: 24607475 </br>9:Isobavachalcone and bavachinin from Psoraleae Fructus modulate Aβ42 aggregation process through different mechanisms in vitro. Chen X, Yang Y, Zhang Y.FEBS Lett. 2013 Sep 17;587(18):2930-5. doi: 10.1016/j.febslet.2013.07.037. Epub 2013 Jul 29. PMID: 23907009 Free Article</br>10:Isobavachalcone suppresses expression of inducible nitric oxide synthase induced by Toll-like receptor agonists. Shin HJ, Shon DH, Youn HS.Int Immunopharmacol. 2013 Jan;15(1):38-41. doi: 10.1016/j.intimp.2012.11.005. Epub 2012 Nov 16. PMID: 23164691 |
